Telix Pharmaceuticals posted Q1 2026 revenue of $230 million, up 11% from the previous quarter, driven by strong sales of its precision medicine products Illuccix and Gozellix. The company advanced key clinical trials for its prostate and brain cancer therapies, including positive safety results in its Phase 3 ProstACT study and resubmission of its brain cancer imaging NDA to the FDA. Telix also expanded its global commercial footprint and reaffirmed its full-year 2026 revenue guidance of $950-$970 million. These developments position Telix for continued growth and progress in oncology treatments.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...
Telo Genomics announced positive interim results from a clinical study analyzing blood samples of multiple myeloma patients to predict relapse risk using 3D telomere analysis. The test showed strong predictive accuracy, potentially offering a less in...
Meta now notifies parents if their teen talks about suicide or self-harm with its AI chatbot and is developing a feature to contact emergency services if risk is detected. This move addresses concerns about AI chatbots handling crisis conversations, ...
NTG Clarity Networks announced new purchase orders and contract renewals totaling about CAD 16.6 million, reflecting strong demand for its software development and digital transformation services. This includes $2.3 million from a real estate client ...
